Matches in Wikidata for { <http://www.wikidata.org/entity/Q64140123> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- Q64140123 description "clinical trial" @default.
- Q64140123 description "ensayu clínicu" @default.
- Q64140123 description "klinisch onderzoek" @default.
- Q64140123 description "клінічне випробування" @default.
- Q64140123 name "Phase 2 Study of MLN0128, Combination of MLN0128 With MLN1117, Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer" @default.
- Q64140123 type Item @default.
- Q64140123 label "Phase 2 Study of MLN0128, Combination of MLN0128 With MLN1117, Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer" @default.
- Q64140123 prefLabel "Phase 2 Study of MLN0128, Combination of MLN0128 With MLN1117, Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer" @default.
- Q64140123 P1132 Q64140123-23295694-B0FB-424D-9550-FD8B3240B25F @default.
- Q64140123 P1476 Q64140123-9F46BBEB-0BC7-4003-8146-D5598EC21D47 @default.
- Q64140123 P17 Q64140123-083F4EBF-1ABA-470B-A8BA-80D8B7FAD2DC @default.
- Q64140123 P17 Q64140123-256C1949-C17C-4C44-A690-799A1F92B9B5 @default.
- Q64140123 P17 Q64140123-2A56E9F4-B575-4B9C-8662-C383AAE0F8DC @default.
- Q64140123 P17 Q64140123-3E280165-B77E-4BCA-802B-C08F48E2D11E @default.
- Q64140123 P17 Q64140123-5E8F7A78-C670-4808-9F35-4DAA1851C934 @default.
- Q64140123 P17 Q64140123-5EF6D46E-30B2-4F7C-B7A7-1F8E3730837D @default.
- Q64140123 P17 Q64140123-7F5A26FC-8937-429E-A9BA-16FB916F37F6 @default.
- Q64140123 P17 Q64140123-895672AC-55C7-429A-BFCE-B5873941C755 @default.
- Q64140123 P17 Q64140123-A4E4DBA5-4F84-40F2-8D6B-896221A989D7 @default.
- Q64140123 P17 Q64140123-FF240F0C-F2F8-4E30-9C9C-D52BF2565F0A @default.
- Q64140123 P2899 Q64140123-B6E735F2-0253-4399-A219-3D06080058D7 @default.
- Q64140123 P3098 Q64140123-171E41BD-310A-4590-999D-EE9028089FAD @default.
- Q64140123 P31 Q64140123-2E21A40F-D58A-4A92-867F-CA8CB5792339 @default.
- Q64140123 P4844 Q64140123-7DD4A84B-09CB-4F11-9F10-51A0340E19C8 @default.
- Q64140123 P580 Q64140123-75D9C7E8-66F2-46F7-8CDC-7DEF026ABCFB @default.
- Q64140123 P582 Q64140123-4EAECE97-4B7F-4525-A7EC-2F18757B676B @default.
- Q64140123 P6099 Q64140123-A7DBA52C-92EF-4793-8551-658E9A6FEDBE @default.
- Q64140123 P6153 Q64140123-0A76AB73-3D84-4E25-A5D3-F8D315E80FF0 @default.
- Q64140123 P6153 Q64140123-2EC6B826-2D69-436F-BB5D-67CC9F7C1DDA @default.
- Q64140123 P6153 Q64140123-3142007E-8C56-41E5-A085-5A1C98D056DA @default.
- Q64140123 P6153 Q64140123-409EDC62-2947-47A2-82C7-70E12050F42F @default.
- Q64140123 P6153 Q64140123-4608BCE7-1D75-4305-AF40-31995905ACE7 @default.
- Q64140123 P6153 Q64140123-47FB432C-0664-4699-82DF-FE034FC8F730 @default.
- Q64140123 P6153 Q64140123-4E143FAC-B5AD-4540-9AE5-D4D9C6DE999D @default.
- Q64140123 P6153 Q64140123-68E15716-F759-4C1A-933D-13BFE77AB52F @default.
- Q64140123 P6153 Q64140123-69ED7A22-33D9-46A6-9F42-4B4CE522B12C @default.
- Q64140123 P6153 Q64140123-6A0033CA-4703-40E7-A6C1-B85ED4D4912F @default.
- Q64140123 P6153 Q64140123-771CCDDD-AA0C-4D59-AC62-AB7109EF0ED3 @default.
- Q64140123 P6153 Q64140123-7C20C54F-E080-49C8-A9BD-D572748E309D @default.
- Q64140123 P6153 Q64140123-860D2EFC-DD78-475D-B53F-046B936F900E @default.
- Q64140123 P6153 Q64140123-894527E7-53AA-4987-A2B6-A58F7DD14729 @default.
- Q64140123 P6153 Q64140123-8B4B5929-BA74-446E-BEF4-FA8505FBFA03 @default.
- Q64140123 P6153 Q64140123-93CC8338-EBF0-441D-8EA2-D2D3328E3501 @default.
- Q64140123 P6153 Q64140123-9F47B6FC-B695-4A8E-84AF-4C5667287E52 @default.
- Q64140123 P6153 Q64140123-B0D19CD2-95F0-4987-91E0-DBA4FC176D18 @default.
- Q64140123 P6153 Q64140123-D11A3A80-311E-4EAD-87C5-966B5AF03CA7 @default.
- Q64140123 P6153 Q64140123-D9A6E7B8-744B-4FCD-9D15-41C2D082F3D0 @default.
- Q64140123 P6153 Q64140123-F5858A48-1F0C-45D1-9CFA-D4FA8928576B @default.
- Q64140123 P8363 Q64140123-1F520790-5196-4906-8027-5BA997417312 @default.
- Q64140123 P1132 "+245" @default.
- Q64140123 P1476 "A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PI3Kα Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced, Recurrent, or Persistent Endometrial Cancer" @default.
- Q64140123 P17 Q145 @default.
- Q64140123 P17 Q16 @default.
- Q64140123 P17 Q183 @default.
- Q64140123 P17 Q20 @default.
- Q64140123 P17 Q29 @default.
- Q64140123 P17 Q30 @default.
- Q64140123 P17 Q31 @default.
- Q64140123 P17 Q38 @default.
- Q64140123 P17 Q408 @default.
- Q64140123 P17 Q55 @default.
- Q64140123 P2899 "+18" @default.
- Q64140123 P3098 "NCT02725268" @default.
- Q64140123 P31 Q30612 @default.
- Q64140123 P4844 Q423762 @default.
- Q64140123 P580 "2016-04-01T00:00:00Z" @default.
- Q64140123 P582 "2019-04-30T00:00:00Z" @default.
- Q64140123 P6099 Q42824440 @default.
- Q64140123 P6153 Q1344478 @default.
- Q64140123 P6153 Q170027 @default.
- Q64140123 P6153 Q1808012 @default.
- Q64140123 P6153 Q192334 @default.
- Q64140123 P6153 Q221653 @default.
- Q64140123 P6153 Q2487297 @default.
- Q64140123 P6153 Q25188472 @default.
- Q64140123 P6153 Q2936440 @default.
- Q64140123 P6153 Q30282164 @default.
- Q64140123 P6153 Q3966437 @default.
- Q64140123 P6153 Q41506 @default.
- Q64140123 P6153 Q5476635 @default.
- Q64140123 P6153 Q5547686 @default.
- Q64140123 P6153 Q640652 @default.
- Q64140123 P6153 Q7109265 @default.
- Q64140123 P6153 Q7593226 @default.
- Q64140123 P6153 Q777403 @default.
- Q64140123 P6153 Q7989074 @default.
- Q64140123 P6153 Q833670 @default.
- Q64140123 P6153 Q865528 @default.
- Q64140123 P6153 Q911561 @default.
- Q64140123 P8363 Q78089383 @default.